Monday June 26th 2017

‘Uncategorized’ Archives

Laquinimod suppresses Genes encoding Cell migration in Multiple Sclerosis

Laquinimod suppresses Genes encoding Cell migration in Multiple Sclerosis

Background: Laquinimod is an immunomodulatory drug currently under investigation for oral treatment for relapsing remitting multiple sclerosis (RRMS). Laquinimod affects the immune system in the periphery and in the central nervous system (CNS), however its molecular [Read More]

Opinion: How can we deny help for MS patients?

Opinion: How can we deny help for MS patients?

The letter from Gael Bullard, a retired nurse, is the best comment from any source I have read on the angioplasty for multiple sclerosis (MS) patients. And yet, what nurse Bullard has to say is so patently obvious. She has written with great clarity and has managed to [Read More]

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]